Genmab Guides 14% 2026 Revenue Growth as Abkinley Faces Approval Hurdles
Genmab’s 2026 revenue guidance forecasts 14% growth, down from 19% in 2025, reflecting potential headwinds. Regulators are reviewing Abkinley’s confounded overall survival data from the EPCOR DLBC1 study, while the Mirrors acquisition adds Perentomab and three phase 3 oncology trials bolster the late-stage pipeline.
1. 2026 Guidance and 2025 Performance
Genmab reported total revenue growth of 19% in 2025 and projects 14% growth in 2026, signaling a slowdown driven by competitive pressures and pandemic-related factors. The guidance reflects expected contributions from both its royalty portfolio and sales of Genmab-commercialized medicines.
2. Abkinley Regulatory Challenges
The EPCOR DLBC1 phase 3 trial for Abkinley achieved positive progression-free survival but missed overall survival due to confounders such as COVID-19 and access to novel therapies. Genmab is engaged in discussions with regulators to address these biases before seeking accelerated approval.
3. Mirrors Acquisition and Market Expansion
In late 2025 Genmab acquired Mirrors, adding Perentomab to its late-stage portfolio and creating multiple upcoming value catalysts. The company also completed four drug launches and expanded commercialization into Germany, the UK, and France.
4. Ongoing Phase 3 Trials
Genmab has three RAS-targeted phase 3 trials in PO, endometrial cancer, and PSOC, and additional registrational studies like EPCOR DLBC4 are expected to yield data this year to support label expansions.